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Abstract: Simple enantioselective synthesis of 6,6-disubstituted pentafulvenes bearing chiral pendant 
hydroxy groups are attained by cascade reactivity using commercially available proline-based 
organocatalysts. Condensation of cyclopentadiene with the acetyl function of a 1,2-
formylacetophenone, followed by cyclization of a resulting fulvene-stabilized carbanion with the 
formyl group, generates bicyclic chiral alcohols with initial er values up to 94:6. Exceptional enantio-
enrichment of the resultant alcohols results upon crystallization – even near racemic samples 
spontaneously de-racemize. This enables new families of substituted cyclopentadienes that are both 
enantiomerically and diastereomerically pure to be rapidly attained. 
 
Synthetic methodology for pentafulvene formation has not altered significantly since these were first 
prepared by Thiele in 1900 by sodium ethoxide facilitated condensation of cyclopentadiene with 
ketones (Scheme 1).[1] Although improved by Little[2] and Ottosson[3] among others none of these allows 
access to chiral fulvenes. Little’s method uses pyrrolidine catalysis to increase the reactivity of the 
ketone, whilst Ottosson’s method uses sodium cyclopentadienide as a more reactive source of the 
cyclopentadiene nucleophile. Both approaches allow for the reaction of more hindered or less activated 
carbonyls. Across the board, examples of syntheses of pentafulvenes bearing chiral pendant functional 
groups are almost unknown, one rare example being Togni’s condensation of sodium cyclopentadienide 
with a homochiral amide (Scheme 1).[4] Unfortunately, this method was limited in scope as only two 
chiral examples of singly substituted 6-derivatives could be accessed. Despite a complete lack of 
effective stereoselective syntheses, pentafulvenes remain a commonly used compound class. Frequent 
applications include: cycloadditions to generate complex, polycyclic scaffolds[5][6] and their use as 
intermediates in the synthesis of substituted (sometimes chiral) cyclopentadienyl derivatives via 
nucleophilic addition to the exocyclic C=C bond as a route to (asymmetric) cyclopentadiene units.[7][8][9] 
Herein we describe a simple approach to families of asymmetric 6,6-disubstituted pentafulvenes bearing 
chiral pendant hydroxy groups (for further functionalization) by straightforward organocatalytic 
methodology. The pentafulvenes are useful as intermediates in the synthesis of substituted 
cyclopentadienes as single enantiomers and diastereomers.  
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Scheme 1. Traditional approaches to (chiral) 6,6- and 6-substituted pentafulvenes. 
 
To develop a route to new chiral pentafulvenes bearing pendant hydroxy groups, we investigated the 
reaction between 2-acetyl-benzaldehyde and cyclopentadiene in the presence of organocatalysts (Table 
1). Reference samples of (±)-2a were prepared via pyrrolidine catalysed reactions, although these were 
slower than the later enantioselective reactions (see Table S1 – Supporting Information). Interestingly, 
we noted that (±)-2a de-racemizes exceptionally readily, with each crystal being a single enantiomer, 
in the same manner as the classical tartrate crystals of Pasteur.[10][11] Single individual crystals of (R) or 
(S)-2a are readily attained stochastically from initially racemic (±)-2a. This occurs predictably for 
scalemic 2a making exceptional enantio-enrichment possible. Conglomerate crystal formation in 2a is 
driven by a strongly stereodirecting helical hydrogen bonding array in its packing (see Figure S5 - 
Supporting Information). Simple (L)-proline gave only low yields of 2a, but greater success was had 
with derivatives of (S)-2-pyrrolidinemethanol (LA). Smaller amounts of achiral 3 and aldol product 4 
could also be isolated from the reaction. Compound 4 is a known product of 1a (formed in low er in 
asymmetric aldol chemistry[12]) but the preparation of pentafulvene products of type 2 is unprecedented, 
as far as we are aware. Catalysts bearing too much steric bulk, such as LE or the bulky diaryl derivatives 
developed by Jørgenson[12] and Hayashi,[13] proved ineffective as did the imidazolidinone derivatives of 
Macmillan.[14] Optimal results were attained with (2S)-1-(pyrrolidin-2-ylmethyl)pyrrolidine (LB),[15][16] 
with a reduced number of equivalents of acetic acid (0.13 vs. 0.38 equiv.). Below 0.38 equivalents of 
catalyst LB the reaction conversion suffered but the er remained high. Alternative acids were also 
trialled but all performed worse than acetic acid in the reaction (see Table S1 – Supporting Information). 
The reaction could be scaled to gram quantities without any significant negative yield or er effects (see 
Experimental Section). Excesses of cyclopentadiene were employed, as it is cheap and easily removed 
during purification, to ensure reliability of the reaction and disfavour the production of by-product 4 as 









Table 1. Summary of optimization for enantioselective preparation of pentafulvene 2a.[a]  
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Catalyst Acid (equiv.) Time (h) Temperature (°C) Yield[b] (%) er 
LA AcOH (0.38) 24 25 90
[c] 79:21 
LB AcOH (0.38) 2 25 71 86:14 
LB AcOH (0.26) 2 22 76 89:11 
LB AcOH (0.13) 6 15 78 94:6 
LC AcOH (0.13) 24 22 69 80:20 
LD AcOH (0.13) 2 22 71 90:10 
LE AcOH (0.13) 4 22 <5 n.d.
[d] 
[a] Carried out on 1a (0.39 mmol) in DMF (1 mL); for full details of optimization see Supporting 
Information. [b] Isolated yield unless otherwise stated. [c] Conversion determined by 1H NMR 
spectroscopy with no internal standard present (mass balance of >90% confirmed independently). [d] 
Not determined. 
 
The precursor 2-acetyl-benzaldehydes (1a-1i) needed for generalization of the reaction are easily 
prepared on multi-gram scales via two routes. Directed lithiation of a range of benzyl alcohols followed 
by reaction with acetaldehyde and subsequent oxidation provides 1a-c in two steps. Alternatively, 
Phan’s phenol formylation, followed by acyl hydrazide formation and subsequent acyl transfer was 
used for 1d-i.[17] The optimal catalyst LB is commercially available, but also readily and efficiently 
prepared on multi-gram scales, starting from low cost (L)-proline via our optimized method (see 













Table 2. Substrate scope for chiral pentafulvene (2) formation.[a] 
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Compound R1 R2 T (°C) T (h) Yield[b] 
(%) 
Initial er Recrystallized er 
2a H H 15 6 78 94:6 >99:1 
(S)-2a[d] H H 15 6 65 94:6 98:2 
2b Ph H 15 4.5 53 88:12 >99:1 
2c tBu H 22 2.5 91 82:18 -[c] 
2d Me H 15 6 72 91:9 -[c] 
2e OMe H 15 5 54 91:9 >99:1 
2f F H 25 4.5 39 92:8 >99:1 
2g H Me 15 6 67 89:11 -[c] 
2h H F 25 3 52 88:12 >99:1 
(S)-2h[d] H F 25 3 39 90:10 >99:1 
2i H Cl 25 3 38 91:9 99:1 
(S)-2i[d] H Cl 25 2.5 30 89:11 99:1 
[a] Carried out on 1 (0.6-2.1 mmol) with AcOH (0.13 equiv.) and LB (0.38 equiv.) in DMF (1-5 mL); 
for full details see Supporting Information. [b] Isolated yield. [c] Could not be enriched by 
recrystallization. [d] Synthesized under identical conditions but providing the (S)-pentafulvene using 
(R)-LB. 
 
Fulvene formation is tolerant of a range of electronic substituent effects in the 5-position (2d-f) but is 
more sensitive to steric factors (runs 2b-c). The opposite situation applies to substitution in the 6-
position (runs 2g-i). The poorer yields obtained for halogen containing 2f and 2i appear to be due to the 
decreased stability of the product rather than lower conversion based on control experiments. 
Modification of the reaction conditions allowed isolation of the two by-products 3 and 4 in useful 
quantities. Reduction of the reaction temperature to 0 °C provided condensation by-product 3 in 45% 
yield after 48 hours. We propose that this is due to the lower temperature strongly disfavoring the less 
reactive keto functionality, allowing for an increase in condensation between the more reactive aldehyde 
and cyclopentadiene longer reaction times. Running the reaction under its optimized conditions (Table 
1, Run 4) but without added cyclopentadiene resulted in a 55% isolated yield of aldol by-product (S)-4 
(er < 85:15). Isolation of these by-products enabled us to unambiguously define the reaction mechanism 
for pentafulvene formation (Scheme 2). Pathway A can be discounted as intermediate 5 would produce 
aldol by-product 4, however, resubmission of isolated 4 to the reaction conditions produces no fulvene 
products discounting cyclopentadiene condensation at the keto group of 4. In addition, HPLC confirms 
the chiral centre in (S)-4 is of opposite configuration to the (R)-2 provided by LB, eliminating 4 as a 
simple precursor to 2.[18][19] Similarly, pathway C can be discounted on the fact that resubmission of 
isolated 3 to the reaction conditions also produces no 2, disavowing potential intermediates in the H-
shift pathway 7a-b. In addition, pathway C would provide regioisomeric 2’ (Scheme 2) if appropriately 
substituted (regardless of the sense of asymmetric induction). Only pathway B, in which condensation 
of cyclopentadiene with the acetyl ketone occurs first, correctly accounts for both the regiochemistry 
and sense of stereochemistry observed in the reaction. The acidity of the α-methyl fulvene group (pKa 
ca. 22.1 in DMSO[20]) and the subsequent inversion in the SN1-like cleavage of the amine both have 
precedent.[21][22][23] Intermediates 6a-b could not be isolated or detected but remain the only viable 
option consistent with the experimental data. Large leaving groups, as in 6b, strongly favour inversion 
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outcomes in SN1 hydrolysis reactions and an ability for additional protonation of the pyrrolidine 
nitrogen may account for the improved performance of LB. 
 
 
Scheme 2. Mechanistic possibilities for the formation of pentafulvene 2a. 
 
Preliminary studies show that, following functionalization of the pendant hydroxy group, pentafulvenes 
of type 2 can be reduced, in the manner of Tacke,[24] using LiBEt3H. One example of this is shown in 
Scheme 3. The reduction proceeds with very high diastereoselectivity (>25:1 as the other diastereomer 
is not visible in the 1H NMR spectrum) following functionalization of pentafulvene 2a with triethylsilyl 
chloride (TESCl). The silyl ether moiety acts as a blocking group, forcing the hydride to add anti to it, 
resulting in the synthesis of syn-cyclopentadiene 9 (see Supporting Information, Figure S2, for an 










Scheme 3. Synthesis of protected pentafulvene 8, via the reaction of pentafulvene 2a with TESCl, 
which is then reduced to syn cyclopentadiene 9. The double bond tautomers of 9 are removed upon 
metal complexation. 
 
To conclude, we have presented an efficient synthesis of chiral 6,6-disubstituted pentafulvenes bearing 
a functionalizable chiral pendant hydroxy group in moderate to good yields and enantiomeric ratios. 
These pentafulvenes possess the interesting and useful characteristic of crystallizing as conglomerates, 
often giving the products in >99:1 er at gram scales. Once functionalized, these chiral pentafulvene 
derivatives can then be converted into substituted cyclopentadienes essentially as both single 
enantiomers and diastereomers. 
 
Experimental Section: 
Representative procedure for synthesis of pentafulvene (R)-2a: Commercially available 2-acetyl-
benzaldehyde (1.29 g, 78% purity, 6.79 mmol) and cyclopentadiene (3.6 mL, 42.8 mmol) were 
dissolved in DMF (16.0 mL) before the addition of acetic acid (47 μL, 0.82 mmol) and dropwise 
addition of commercially available (2S)-1-(pyrrolidin-2-ylmethyl)pyrrolidine (411 μL, 2.52 mmol). 
This was then stirred at 15 °C for 6 hours, after which the reaction was diluted into ethyl acetate (250 
mL) and washed with pH 7.4 phosphate buffer (3 × 100 mL). The solvent was removed in vacuo before 
purification via flash column chromatography (eluent: dichloromethane) to yield the crude product as 
a bright orange solid in 64% yield (850 mg, 4.33 mmol); yield range on 0.1-1 g scales: 64-78%. 
Purification from CH2Cl2/pentane, or dimethoxyethane readily afforded (R)-2a as red needles (590 mg, 
3.01 mmol, 70% recovery) with >99:1 er. M.p.: 130-140 °C (darkens from this temperature); Rf 
(dichloromethane): 0.30; 1H NMR  (400.2 MHz, CDCl3): δH 7.96 (dd, J = 6.6, 1.9 Hz, 1H, ArH), 7.58-
7.55 (m, 1H, ArH), 7.48-7.38 (m, 2H, ArH), 6.92 (app ddd, J = 5.3, 1.7, 1.7 Hz, 1H, CpH), 6.59-6.55 
(m, 1H, CpH), 6.53-6.49 (m, 2H, CpH), 5.35 (ddd, J = 7.0, 7.0, 3.7 Hz, 1H, CHOH), 3.72 (dd, J = 17.5, 
7.0 Hz, 1H, CHaHb anti to OH), 3.09 (dd, J = 17.5, 7.0 Hz, 1H, CHaHb syn to OH), 2.01 (d, J = 3.7 Hz, 
1H, OH); 13C NMR (100.05 MHz, CDCl3): δC 151.2 (C), 149.5 (C), 139.4 (C), 138.7 (C), 132.8 (CH), 
131.1 (CH), 131.0 (CH), 129.4 (CH), 126.5 (CH), 125.4 (CH), 123.4 (CH), 120.0 (CH), 72.9 (CH), 44.0 
(CH2); νmax (CHCl3): 3614, 3590, 3070, 3045, 3008, 2960, 2927, 2873, 1630, 1476, 1458, 1389, 1368, 
1239, 1050, 1021, 997 cm-1; HRMS found 197.0959 C14H13O+ requires 197.0961 (|σ| = 1.0 ppm); 
HPLC (before crystallization): Chiralpak AD-H; mobile phase, hexane:2-propanol (4:1 v/v); flow rate, 
0.5 mL.min-1; retention times (S) enantiomer: 11.8 min (6.2%), (R) enantiomer: 14.2 min (93.8%), er 
94:6; [α]D23: +68.0 (er >99:1, c = 0.50 in CHCl3); Anal: Calcd. for C14H12O C, 85.68%; H, 6.16%; 
found C, 85.20%; H, 6.47%.  
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